Does TORIPALIMAB Cause Myelosuppression? 590 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 590 reports of Myelosuppression have been filed in association with TORIPALIMAB (LOQTORZI). This represents 43.9% of all adverse event reports for TORIPALIMAB.
590
Reports of Myelosuppression with TORIPALIMAB
43.9%
of all TORIPALIMAB reports
3
Deaths
432
Hospitalizations
How Dangerous Is Myelosuppression From TORIPALIMAB?
Of the 590 reports, 3 (0.5%) resulted in death, 432 (73.2%) required hospitalization, and 43 (7.3%) were considered life-threatening.
Is Myelosuppression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TORIPALIMAB. However, 590 reports have been filed with the FAERS database.
What Other Side Effects Does TORIPALIMAB Cause?
Off label use (276)
White blood cell count decreased (144)
Anaemia (67)
Hypothyroidism (67)
Neutrophil count decreased (67)
Nausea (60)
Rash (59)
Vomiting (58)
Platelet count decreased (53)
Diarrhoea (50)
What Other Drugs Cause Myelosuppression?
CYCLOPHOSPHAMIDE (3,603)
CARBOPLATIN (2,624)
TRASTUZUMAB (2,552)
PACLITAXEL (2,522)
TISLELIZUMAB (2,142)
CYTARABINE (1,869)
VENETOCLAX (1,864)
CISPLATIN (1,849)
BEVACIZUMAB (1,744)
SODIUM (1,696)
Which TORIPALIMAB Alternatives Have Lower Myelosuppression Risk?
TORIPALIMAB vs TORSEMIDE
TORIPALIMAB vs TOVIAZ
TORIPALIMAB vs TOVORAFENIB
TORIPALIMAB vs TOZINAMERAN
TORIPALIMAB vs TRABECTEDIN